Cerebral Blood Flow Measurement of MRI using PSO17 in Normal Subjects and Patients with Chronic Cerebrovascular Disorders

Cerebral Blood Flow Measurement of MRI using PSO17 in Normal Subjects and Patients with Chronic Cerebrovascular Disorders - Cerebral Blood Flow Measurement using PSO17

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009953

Enrollment

Registered

2013-02-04

Start date

2012-12-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

normal subjects and patients with chronic cerebrovascular disorders

Interventions

intravenous administration of PSO17

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: (1) healthy Japanese male (20 - 65 years old) (2) body weight < 60 kg (3) informed consent is obtained

Exclusion criteria

Exclusion criteria: (1) metallic implant or claustrophobia (2) chronic disorders (3) CNS, liver, kidney or heart diease (4) acute infection before 30 days (5) drug allergy (6) chronic intake of drugs (> 30 days) (7) other clinical trial (8) screening test (9) willing to have babies

Design outcomes

Primary

Measure	Time frame
(1) Signal difference of brain parenchyma between pre- and post-administration of PSO17 and saline (2) Temporal signal change after administration of PSO17 and saline	—

Secondary

Measure	Time frame
(1) Efficacy 1) Correlation between blood flow image and PET in patient group (2) Safety 1) Vital signs (BP, HR, body temperature) 2) blood test and urine test 3) adverse effect	—

Countries

Japan

Contacts

Public ContactKohsuke Kudo

Iwate Medical University Ultrahigh Field MRI

kokudo@iwate-med.ac.jp019-651-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026